Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25853943 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL24393470 | 0.90 | HDAC6 (0.46) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL2157165 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL16132816 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL25854290 | 0.85 | EHMT2 (0.44) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL1395632 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL19193751 | 0.80 | EHMT2 (0.44) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL24336889 | 0.79 | KMT2A (0.52) | HPGDKMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL18958956 | 0.79 | LMNA (0.40) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL14983689 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2HPGDKMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-07-11 | — | — | US | disclosed |
| US-11672868-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2023-06-13 | — | — | US | disclosed |
| WO-2020148528-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3 | Bicyclerd Limited (GB) | 2020-07-23 | — | — | WO | disclosed |
| US-20140128580-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8652479-B2 | Antibody-drug conjugates and methods | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8142784-B2 | Antibody-drug conjugates and methods | GENENTECH, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | GENENTECH, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | ERBB2, EGFR, ERBB4 | SMN1; SMN2 4586/4885HPGD 990/4885HSD17B10 1681/4885 |
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, ERBB2 | SMN1; SMN2 3128/4885HPGD 3571/4885HSD17B10 3653/4885 |
| US-11672868-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | SMN1; SMN2 2304/4885HPGD 1617/4885HSD17B10 2466/4885 |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | ERBB2, EGFR, ERBB4 | SMN1; SMN2 4722/4885HPGD 1051/4885HSD17B10 2257/4885 |
| US-20140128580-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | ERBB2, EGFR, ERBB4 | SMN1; SMN2 4586/4885HPGD 990/4885HSD17B10 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.